Read by QxMD icon Read

Thompson melanoma

Kirsten A M White, Li Luo, Todd A Thompson, Salina Torres, Chien-An Andy Hu, Nancy E Thomas, Jenna Lilyquist, Hoda Anton-Culver, Stephen B Gruber, Lynn From, Klaus J Busam, Irene Orlow, Peter A Kanetsky, Loraine D Marrett, Richard P Gallagher, Lidia Sacchetto, Stefano Rosso, Terence Dwyer, Anne E Cust, Colin B Begg, Marianne Berwick
Autophagy has been linked with melanoma risk and survival, but no polymorphisms in autophagy-related (ATG) genes have been investigated in relation to melanoma progression. We examined five single-nucleotide polymorphisms (SNPs) in three ATG genes (ATG5; ATG10; and ATG16L) with known or suspected impact on autophagic flux in an international population-based case-control study of melanoma. DNA from 911 melanoma patients was genotyped. An association was identified between (GG) (rs2241880) and earlier stage at diagnosis (OR 0...
October 17, 2016: Cancer Medicine
C M Madronio, B K Armstrong, C G Watts, C Goumas, R L Morton, A Curtin, S W Menzies, G J Mann, J F Thompson, A E Cust
BACKGROUND: Guidelines recommend that health professionals identify and manage individuals at high risk of developing melanoma, but there is limited population-based evidence demonstrating real-world practices. OBJECTIVE: A population-based, observational study was conducted in the state of New South Wales, Australia to determine doctors' knowledge of melanoma patients' risk and to identify factors associated with better identification and clinical management. METHODS: Data were analysed for 1889 patients with invasive, localised melanoma in the Melanoma Patterns of Care study...
September 27, 2016: Cancer Epidemiology
Nicholas James Anthony Halfpenny, Joan Mary Quigley, Juliette Catherine Thompson, David Alexander Scott
Peer-reviewed publications and conference proceedings are the mainstay of data sources for systematic reviews and network meta-analyses (NMA), but access to informative unpublished data is now becoming commonplace. To explore the usefulness of three types of 'grey' literature-clinical trials registries, clinical study reports and data from regulatory authorities-we conducted four case studies. The reporting of outcome data in peer-reviewed publications, the clinical trials registries and the clinical study reports for two clinical trials-one in melanoma, one in juvenile idiopathic arthritis (JIA)-was examined...
September 29, 2016: Evidence-based Medicine
Nalin Leelatian, Deon B Doxie, Allison R Greenplate, Bret C Mobley, Jonathan M Lehman, Justine Sinnaeve, Rondi M Kauffmann, Jay A Werkhaven, Akshitkumar M Mistry, Kyle D Weaver, Reid C Thompson, Pierre P Massion, Mary A Hooks, Mark C Kelley, Lola B Chambless, Rebecca A Ihrie, Jonathan M Irish
BACKGROUND: Mass cytometry measures 36 or more markers per cell and is an appealing platform for comprehensive phenotyping of cells in human tissue and tumor biopsies. While tissue disaggregation and fluorescence cytometry protocols were pioneered decades ago, it is not known whether established protocols will be effective for mass cytometry and maintain cancer and stromal cell diversity. METHODS: Tissue preparation techniques were systematically compared for gliomas and melanomas, patient derived xenografts of small cell lung cancer, and tonsil tissue as a control...
September 6, 2016: Cytometry. Part B, Clinical Cytometry
Daniel G Coit, John A Thompson, Alain Algazi, Robert Andtbacka, Christopher K Bichakjian, William E Carson, Gregory A Daniels, Dominick DiMaio, Ryan C Fields, Martin D Fleming, Brian Gastman, Rene Gonzalez, Valerie Guild, Douglas Johnson, Richard W Joseph, Julie R Lange, Mary C Martini, Miguel A Materin, Anthony J Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I Ross, April K Salama, Joseph Skitzki, Susan M Swetter, Kenneth K Tanabe, Javier F Torres-Roca, Vijay Trisal, Marshall M Urist, Nicole McMillian, Anita Engh
The NCCN Guidelines for Melanoma have been significantly revised over the past few years in response to emerging data on a number of novel agents and treatment regimens. These NCCN Guidelines Insights summarize the data and rationale supporting extensive changes to the recommendations for systemic therapy in patients with metastatic or unresectable melanoma.
August 2016: Journal of the National Comprehensive Cancer Network: JNCCN
Caroline G Watts, Christine M Madronio, Rachael L Morton, Chris Goumas, Bruce K Armstrong, Austin Curtin, Scott W Menzies, Graham J Mann, John F Thompson, Anne E Cust
BACKGROUND/OBJECTIVES: To describe the method of diagnosis, clinical management and adherence to clinical practice guidelines for melanoma patients at high risk of a subsequent primary melanoma, and compare this with melanoma patients at lower risk. METHODS: The Melanoma Patterns of Care study was a population-based, observational study based on doctors' reported clinical management of melanoma patients in New South Wales, Australia, diagnosed with in situ or invasive melanoma over a 12-month period from October 2006...
August 1, 2016: Australasian Journal of Dermatology
Gerald B Fogarty, Angela Hong, Vinai Gondi, Bryan Burmeister, Kari Jacobsen, Serigne Lo, Elizabeth Paton, Brindha Shivalingam, John F Thompson
Every year 170,000 patients are diagnosed with brain metastases (BMs) in the United States. Traditionally, adjuvant whole brain radiotherapy (AWBRT) has been offered following local therapy with neurosurgery (NSx) and/or stereotactic radiosurgery (SRS) to BMs. The aim is to increase intracranial control, thereby decreasing symptoms from intracranial progression and a neurological death. There is a rapidly evolving change in the radiation treatment of BMs happening around the world. AWBRT is now being passed over in favour of repeat scanning at regular intervals and more local therapies as more BMs appear radiologically, BMs that may never become symptomatic...
2016: BMC Cancer
Miguel Martinez-Rodriguez, Alec K Thompson, Carlos Monteagudo
AIMS: It has been proposed that the expression of chemokines and chemokine receptors by melanoma cells may have a role in tumour immune escape. Chemokine CCL27 is reported to be expressed specifically on the epidermal keratinocytes. The implication of CCL27 in cutaneous melanomas is currently unresolved. It has been suggested that CCL27 expression in melanomas can induce antitumoral immunity, and that CCL27 may suppress tumour growth probably due to the local lymphocyte recruitment. METHODS: We studied CCL27 chemokine expression in three different concentric epidermal areas covering the primary cutaneous melanoma in patients with a long clinical follow-up...
June 20, 2016: Journal of Clinical Pathology
Ritva Vyas, Cheryl L Thompson, Homayoun Zargar, Jacqueline Selph, Meg R Gerstenblith
BACKGROUND: Primary melanoma arising in the genitourinary tract is rare and poorly characterized. OBJECTIVES: We sought to describe the epidemiology of genitourinary melanoma in the United States. METHODS: Incident case and population data were obtained for genitourinary melanoma from the Surveillance, Epidemiology, and End Results 13 Registries Database between 1992 and 2012. RESULTS: A total of 817 patients with genitourinary melanoma were identified; most cases occurred in the vulva...
July 2016: Journal of the American Academy of Dermatology
Aude G Chapuis, Ilana M Roberts, John A Thompson, Kim A Margolin, Shailender Bhatia, Sylvia M Lee, Heather L Sloan, Ivy P Lai, Erik A Farrar, Felecia Wagener, Kendall C Shibuya, Jianhong Cao, Jedd D Wolchok, Philip D Greenberg, Cassian Yee
PURPOSE: Peripheral blood-derived antigen-specific cytotoxic T cells (CTLs) provide a readily available source of effector cells that can be administered with minimal toxicity in an outpatient setting. In metastatic melanoma, this approach results in measurable albeit modest clinical responses in patients resistant to conventional therapy. We reasoned that concurrent cytotoxic T-cell lymphocyte antigen-4 (CTLA-4) checkpoint blockade might enhance the antitumor activity of adoptively transferred CTLs...
June 6, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Aude G Chapuis, Sylvia M Lee, John A Thompson, Ilana M Roberts, Kim A Margolin, Shailender Bhatia, Heather L Sloan, Ivy Lai, Felecia Wagener, Kendall Shibuya, Jianhong Cao, Jedd D Wolchok, Philip D Greenberg, Cassian Yee
Adoptive transfer of peripheral blood-derived, melanoma-reactive CD8(+) cytotoxic T lymphocytes (CTLs) alone is generally insufficient to eliminate bulky tumors. Similarly, monotherapy with anti-CTLA4 infrequently yields sustained remissions in patients with metastatic melanoma. We postulated that a bolus of enhanced IL-21-primed polyclonal antigen-specific CTL combined with CTLA4 blockade might boost antitumor efficacy. In this first-in-human case study, the combination successfully led to a durable complete remission (CR) in a patient whose disease was refractory to both monoclonal CTL and anti-CTLA4...
June 27, 2016: Journal of Experimental Medicine
John A Thompson
Over the past 5 years, a host of new agents have radically changed the therapeutic landscape in advanced melanoma; gone are the days when the only active agents were interferon and dacarbazine. Nearly 25 years ago, few patients with stage IV melanoma reached 2-year survival; today, these survival curves have risen substantially. At the NCCN 21st Annual Conference, John A. Thompson, MD, discussed updates with longer duration of patient follow-up for immune checkpoint therapies. He also reviewed some of the newer approvals in advanced melanoma, including the combination of ipilimumab and nivolumab, high-dose ipilimumab, the oncolytic virus therapy talimogene laherparepvec, and the molecularly targeted combination of the BRAF and MEK inhibitors vemurafenib and cobimetinib...
May 2016: Journal of the National Comprehensive Cancer Network: JNCCN
Roxana S Dronca, Xin Liu, Susan M Harrington, Lingling Chen, Siyu Cao, Lisa A Kottschade, Robert R McWilliams, Matthew S Block, Wendy K Nevala, Michael A Thompson, Aaron S Mansfield, Sean S Park, Svetomir N Markovic, Haidong Dong
Immune checkpoint therapy with PD-1 blockade has emerged as an effective therapy for many advanced cancers; however, only a small fraction of patients achieve durable responses. To date, there is no validated blood-based means of predicting the response to PD-1 blockade. We report that Bim is a downstream signaling molecule of the PD-1 pathway, and its detection in T cells is significantly associated with expression of PD-1 and effector T cell markers. High levels of Bim in circulating tumor-reactive (PD-1(+)CD11a(hi)CD8(+)) T cells were prognostic of poor survival in patients with metastatic melanoma who did not receive anti-PD-1 therapy and were also predictive of clinical benefit in patients with metastatic melanoma who were treated with anti-PD-1 therapy...
May 5, 2016: JCI Insight
Shailender Bhatia, John A Thompson
No abstract text is available yet for this article.
April 19, 2016: JAMA: the Journal of the American Medical Association
Ludi Ge, Ricardo E Vilain, Serigne Lo, Karina Aivazian, Richard A Scolyer, John F Thompson
BACKGROUND: Breslow thickness is the most important prognostic factor in patients with clinically localized primary cutaneous melanomas, and its accuracy has important implications for staging and management. A review of the Melanoma Institute Australia database and population-based data for the state of New South Wales, Australia, found an unexpectedly large number of melanomas reported as being exactly 1.0 mm thick. We sought to determine possible causes for this biologically implausible finding...
August 2016: Annals of Surgical Oncology
Jeffrey F Scott, Cheryl L Thompson, Ritva Vyas, Kord Honda, Chad Zender, Rod Rezaee, Pierre Lavertu, Henry Koon, Kevin D Cooper, Meg R Gerstenblith
PURPOSE: Rarely, melanoma is discovered in the parotid gland without an identifiable primary site. It is not known how patients with parotid melanoma of unknown primary (PMUP) compare to those with a known primary (PMKP). As such, we describe the largest series of patients with PMUP to date and compare them to patients with PMKP. METHODS: We analyzed cases from three sources: (1) the University Hospitals Case Medical Center pathology database (n = 45), (2) the Surveillance, Epidemiology, and End Results 18 database (n = 33), and (3) a comprehensive literature search (n = 32)...
July 2016: Journal of Cancer Research and Clinical Oncology
Daniel G Coit, John A Thompson, Alain Algazi, Robert Andtbacka, Christopher K Bichakjian, William E Carson, Gregory A Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C Fields, Martin D Fleming, Rene Gonzalez, Valerie Guild, Allan C Halpern, F Stephen Hodi, Richard W Joseph, Julie R Lange, Mary C Martini, Miguel A Materin, Anthony J Olszanski, Merrick I Ross, April K Salama, Joseph Skitzki, Jeff Sosman, Susan M Swetter, Kenneth K Tanabe, Javier F Torres-Roca, Vijay Trisal, Marshall M Urist, Nicole McMillian, Anita Engh
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and high-dose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted re-assessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections...
April 2016: Journal of the National Comprehensive Cancer Network: JNCCN
Shailender Bhatia, Anna C Pavlick, Peter Boasberg, John A Thompson, George Mulligan, Michael D Pickard, Hélène Faessel, Bruce J Dezube, Omid Hamid
Purpose The therapeutic index of proteasome inhibitors may be improved through selective inhibition of a sub-component of the ubiquitin-proteasome system, such as the NEDD8-conjugation pathway. This multicenter, phase I, dose-escalation study assessed safety and the maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and antitumor activity of pevonedistat, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients with metastatic melanoma. Methods Patients received intravenous pevonedistat on Days 1, 4, 8, 11 (schedule A) or 1, 8, 15 (schedule B) of 21-day cycles...
August 2016: Investigational New Drugs
Megan Lyle, Lauren E Haydu, Alexander M Menzies, John F Thompson, Robyn P M Saw, Andrew J Spillane, Richard F Kefford, Graham J Mann, Wendy A Cooper, Bing Yu, Richard A Scolyer, Sandra A O'Toole, Georgina V Long
Targeted therapy directed at driver oncogenic mutations offers an effective treatment option for select patients with metastatic melanoma. The aim of this study was to assess the prevalence of clinically significant somatic mutations, specifically BRAF, NRAS and KIT, in a large cohort of Australian patients with metastatic melanoma. We performed a cross-sectional cohort study of consecutive patients with American Joint Committee on Cancer (AJCC) stage IIIc unresectable or stage IV melanoma managed at Melanoma Institute Australia, and affiliated sites, that underwent molecular testing between 22 June 2009 and 19 July 2013...
February 2016: Pathology
Jason Madore, Dario Strbenac, Ricardo Vilain, Alexander M Menzies, Jeen Y H Yang, John F Thompson, Georgina V Long, Graham J Mann, Richard A Scolyer, James S Wilmott
PURPOSE: Understanding why some melanomas test negative for PD-L1 by IHC may have implications for the application of anti-PD-1 therapies in melanoma management. This study sought to determine somatic mutation and gene expression patterns associated with tumor cell PD-L1 expression, or lack thereof, in stage III metastatic melanoma to better define therapeutically relevant patient subgroups. EXPERIMENTAL DESIGN: IHC for PD-L1 was assessed in 52 American Joint Committee on Cancer stage III melanoma lymph node specimens and compared with specimen-matched comprehensive clinicopathologic, genomic, and transcriptomic data...
August 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"